Articles tagged "Highly-sensitized"

2016 American Transplant Congress
Impact of Angiotensin II Type I Receptor Antibody Positivity in Highly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).
A. Vo,¹ C. Boutsicaris,¹ X. Zhang,² N. Reinsmoen,² J. Choi,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²HLA Laboratory, Cedars-Sinai Medical Center, LA, CA.
Introduction: Angiotensin II type I receptor antibody (AT1R Ab) is a target for non-HLA antibodies. AT1R ab exert direct effects on endothelial and vascular smooth…
2016 American Transplant Congress
Role of Preformed IgM Donor Human Leucocyte Antigen (HLA) Specific Antibodies in HLA Incompatible Renal Transplantation.
A. Andreou, A. Babu, T. Barber, R. Higgins, D. Briggs, D. Mitchell, N. Khovanova, T. Shaikhina, S. Daga.
Renal, University Hospitals Coventry and Wawickshire, Coventry, United Kingdom; Life Sciences, University of Warwick, Coventry, United Kingdom; School of Mathematics and Engineering, University of Warwick, Coventry, United Kingdom.
Introduction: Pre-transplant IgG antibody screening is common due to its established role of predicting rejection and graft survival; the role of pre-formed IgM human leukocyte…
2016 American Transplant Congress
First Experience with Obinutuzumab (Type II Anti-CD20) in Patients with Treatment-Resistant Glomerular Diseases and Antibody-Mediated Rejection.
J. Choi, S. Jordan, A. Vo.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: There is extensive experience with rituximab (RTX,Type I anti-CD20) for desensitization (DES) and treatment of ABMR. There is also a comparable experience in treatment…
2016 American Transplant Congress
Alemtuzumab Is Safe and Effective Induction Therapy in Highly Sensitized (HS) Pediatric Patients Undergoing Transplantation.
I. Kim,¹ J. Choi,¹ A. Vo,¹ A. Kang,¹ M. Toyoda,¹ J. Mirocha,² E. Kamil,¹ S. Louie,¹ O. Galera,¹ S. Jordan,¹ D. Puliyanda.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Biostatistics Core, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: Studies show that alemtuzumab, a potent lymphocyte-depleting agent, is well-tolerated in pediatric renal transplantation. We report on the use of alemtuzumab induction in HS…
2016 American Transplant Congress
Initial Experience with the Bacterial Enzyme IdeS® (IgG Endopeptidase) for Desensitization of Highly-HLA Sensitized (HS) Patients.
S. Jordan,¹ J. Choi,¹ X. Zhang,¹ M. Haas,² A. Peng,¹ J. Kahwaji,¹ R. Villicana,¹ A. Vo.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Pathology, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: The IgG degrading enzyme derived from Streptococcus pyogenes (IdeS®) is a 35k-Da cysteine protease that cleaves human IgG molecules at the lower hinge region…
2016 American Transplant Congress
Long-Term Assessment of the Safety and Efficacy of IVIG and Rituximab-Based Desensitization (DES).
J. Choi, J. Kahwaji, A. Vo, S. Louie, A. Kang, A. Peng, R. Villicana, D. Puliyanda, I. Kim, S. Jordan.
Comprehensive Transplantation Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: HLA sensitized patients constitute a growing number of ESRD patients with an immunologic barrier to successful transplantation. Desensitization (DES) therapies have emerged to address…
2016 American Transplant Congress
Impact of the New Kidney Allocation System (KAS) on Transplant Rates & Outcomes in Broadly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).
A. Vo,¹ X. Zhang,² S. Williamson,¹ K. Myers,¹ N. Reinsmoen,² J. Choi,¹ J. Kahwaji,¹ A. Peng,¹ R. Villicana,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²HLA Laboratory, Cedars-Sinai Medical Center, LA, CA.
Introduction: HS patients not desensitized (DES) receiving transplants are at risk for ABMR. DES improves transplant rates, but is limited to donor availability. Implementation of…
2016 American Transplant Congress
Anti-IL6R Therapy (Tocilizumab) Improves Long-Term Patient & Graft Survival in Patients with Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy.
J. Choi, A. Vo, M. Haas, D. Puliyanda, S. Louie, A. Peng, J. Kahwaji, R. Villicana, I. Kim, J. Mirocha, S. Jordan.
Comprehensive Transplantation Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction:Extending the functionality of renal allografts is an essential goal of transplant medicine. HS patients (pts) are at increased risk for chronic ABMR (CABMR) due…
2016 American Transplant Congress
Incidence & Impact of De Novo DSA (dnDSA) Formation on Transplant Outcomes in HLA-Sensitized (HS) Patients Transplanted After IVG+Rituximab Desensitization (DES).
A. Vo,¹ J. Choi,¹ J. Kahwaji,¹ J. Mirocha,² A. Peng,¹ R. Villicana,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²Research Institute, Cedars-Sinai Medical Center, LA, CA.
Introduction: Highly-HLA sensitized patients are at risk for developing donor specific antibodies (DSA) & ABMR post-transplant (tx). However, incidence and risk of acute rejections (AR)…
2016 American Transplant Congress
Hospital Readmissions Following Incompatible Kidney Transplantation: A Multi-Center Study.
B. Orandi, E. King, X. Luo, S. Bae, B. Lonze, R. Montgomery, D. Segev.
Johns Hopkins, Baltimore.
Desensitization and incompatible live donor kidney transplantation (ILDKT) has improved survival vs. forgoing transplant or waiting for a compatible one. It is unknown if increased…